semaglutide fda weight loss Approves Oral for Novo asks FDA to bar
Description
In conclusion, we believe it is premature to conclude that the GLP-1 class of drugs has been established as having a good safety profile and is appropriate for a relatively early choice of therapy for type 2 diabetes
If prescribed GLP-1 provides your best treatment for weight loss, well start your prescription
In these cases, starting low and slow matters
Lower discontinuation rate tha
